WO2022221969A1 - Vesículas extracelulares de células mesenquimales de cordón umbilical para el tratamiento de enfermedades osteoarticulares y autoinmunes. - Google Patents
Vesículas extracelulares de células mesenquimales de cordón umbilical para el tratamiento de enfermedades osteoarticulares y autoinmunes. Download PDFInfo
- Publication number
- WO2022221969A1 WO2022221969A1 PCT/CL2022/050039 CL2022050039W WO2022221969A1 WO 2022221969 A1 WO2022221969 A1 WO 2022221969A1 CL 2022050039 W CL2022050039 W CL 2022050039W WO 2022221969 A1 WO2022221969 A1 WO 2022221969A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hsa
- mir
- composition
- useful
- cells
- Prior art date
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 15
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 72
- 239000002679 microRNA Substances 0.000 claims abstract description 30
- 108091070501 miRNA Proteins 0.000 claims abstract description 29
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 102100025222 CD63 antigen Human genes 0.000 claims abstract description 5
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims abstract description 5
- 108091044796 Homo sapiens miR-1290 stem-loop Proteins 0.000 claims abstract description 5
- 108091048713 Homo sapiens miR-2861 stem-loop Proteins 0.000 claims abstract description 5
- 108091055349 Homo sapiens miR-4530 stem-loop Proteins 0.000 claims abstract description 5
- 108091040081 Homo sapiens miR-6088 stem-loop Proteins 0.000 claims abstract description 5
- 108091058617 Homo sapiens miR-6131 stem-loop Proteins 0.000 claims abstract description 5
- 102100027221 CD81 antigen Human genes 0.000 claims abstract description 4
- 102100037904 CD9 antigen Human genes 0.000 claims abstract description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims abstract description 4
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims abstract description 4
- 108091044678 Homo sapiens miR-1307 stem-loop Proteins 0.000 claims abstract description 4
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 claims abstract description 4
- 108091063808 Homo sapiens miR-574 stem-loop Proteins 0.000 claims abstract description 4
- 108091024560 Homo sapiens miR-6741 stem-loop Proteins 0.000 claims abstract description 4
- 108091024433 Homo sapiens miR-6782 stem-loop Proteins 0.000 claims abstract description 4
- 108091008065 MIR21 Proteins 0.000 claims abstract description 4
- 108091069090 Homo sapiens miR-149 stem-loop Proteins 0.000 claims abstract description 3
- 108091058658 Homo sapiens miR-6126 stem-loop Proteins 0.000 claims abstract description 3
- 108091024409 Homo sapiens miR-6780b stem-loop Proteins 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 30
- 230000035755 proliferation Effects 0.000 claims description 18
- 201000008482 osteoarthritis Diseases 0.000 claims description 17
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 10
- 239000011707 mineral Substances 0.000 claims description 10
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 102100032912 CD44 antigen Human genes 0.000 claims description 7
- 102000000905 Cadherin Human genes 0.000 claims description 7
- 108050007957 Cadherin Proteins 0.000 claims description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 7
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 7
- 108050000637 N-cadherin Proteins 0.000 claims description 7
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 7
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 102100037241 Endoglin Human genes 0.000 claims description 5
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 5
- 108010025832 RANK Ligand Proteins 0.000 claims description 5
- 102000014128 RANK Ligand Human genes 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 210000004322 M2 macrophage Anatomy 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 230000003848 cartilage regeneration Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000008355 cartilage degradation Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 238000005199 ultracentrifugation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000001808 exosome Anatomy 0.000 description 19
- 210000003127 knee Anatomy 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- 230000033558 biomineral tissue development Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 7
- 239000003086 colorant Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000010603 microCT Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 108091069047 Homo sapiens let-7i stem-loop Proteins 0.000 description 2
- 108091082537 Homo sapiens miR-1273h stem-loop Proteins 0.000 description 2
- 108091044777 Homo sapiens miR-1275 stem-loop Proteins 0.000 description 2
- 108091072638 Homo sapiens miR-3197 stem-loop Proteins 0.000 description 2
- 108091067272 Homo sapiens miR-376c stem-loop Proteins 0.000 description 2
- 108091055377 Homo sapiens miR-4449 stem-loop Proteins 0.000 description 2
- 108091059213 Homo sapiens miR-7150 stem-loop Proteins 0.000 description 2
- 108091080241 Homo sapiens miR-8078 stem-loop Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 description 1
- 108091044937 Homo sapiens miR-1237 stem-loop Proteins 0.000 description 1
- 108091069004 Homo sapiens miR-125a stem-loop Proteins 0.000 description 1
- 108091069006 Homo sapiens miR-125b-1 stem-loop Proteins 0.000 description 1
- 108091069087 Homo sapiens miR-125b-2 stem-loop Proteins 0.000 description 1
- 108091044802 Homo sapiens miR-1285-1 stem-loop Proteins 0.000 description 1
- 108091069022 Homo sapiens miR-130a stem-loop Proteins 0.000 description 1
- 108091068992 Homo sapiens miR-143 stem-loop Proteins 0.000 description 1
- 108091069002 Homo sapiens miR-145 stem-loop Proteins 0.000 description 1
- 108091069089 Homo sapiens miR-146a stem-loop Proteins 0.000 description 1
- 108091070491 Homo sapiens miR-16-1 stem-loop Proteins 0.000 description 1
- 108091068927 Homo sapiens miR-16-2 stem-loop Proteins 0.000 description 1
- 108091067469 Homo sapiens miR-181a-1 stem-loop Proteins 0.000 description 1
- 108091067618 Homo sapiens miR-181a-2 stem-loop Proteins 0.000 description 1
- 108091079265 Homo sapiens miR-1915 stem-loop Proteins 0.000 description 1
- 108091069034 Homo sapiens miR-193a stem-loop Proteins 0.000 description 1
- 108091067692 Homo sapiens miR-199a-1 stem-loop Proteins 0.000 description 1
- 108091067467 Homo sapiens miR-199a-2 stem-loop Proteins 0.000 description 1
- 108091070519 Homo sapiens miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091070495 Homo sapiens miR-19b-2 stem-loop Proteins 0.000 description 1
- 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 description 1
- 108091067572 Homo sapiens miR-221 stem-loop Proteins 0.000 description 1
- 108091067573 Homo sapiens miR-222 stem-loop Proteins 0.000 description 1
- 108091070492 Homo sapiens miR-23a stem-loop Proteins 0.000 description 1
- 108091069063 Homo sapiens miR-23b stem-loop Proteins 0.000 description 1
- 108091070373 Homo sapiens miR-24-1 stem-loop Proteins 0.000 description 1
- 108091070374 Homo sapiens miR-24-2 stem-loop Proteins 0.000 description 1
- 108091070372 Homo sapiens miR-26a-1 stem-loop Proteins 0.000 description 1
- 108091065428 Homo sapiens miR-26a-2 stem-loop Proteins 0.000 description 1
- 108091070400 Homo sapiens miR-27a stem-loop Proteins 0.000 description 1
- 108091069018 Homo sapiens miR-27b stem-loop Proteins 0.000 description 1
- 108091070398 Homo sapiens miR-29a stem-loop Proteins 0.000 description 1
- 108091068837 Homo sapiens miR-29b-1 stem-loop Proteins 0.000 description 1
- 108091068845 Homo sapiens miR-29b-2 stem-loop Proteins 0.000 description 1
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 description 1
- 108091066993 Homo sapiens miR-339 stem-loop Proteins 0.000 description 1
- 108091032108 Homo sapiens miR-424 stem-loop Proteins 0.000 description 1
- 108091089468 Homo sapiens miR-5585 stem-loop Proteins 0.000 description 1
- 108091060463 Homo sapiens miR-671 stem-loop Proteins 0.000 description 1
- 108091024747 Homo sapiens miR-6727 stem-loop Proteins 0.000 description 1
- 108091024548 Homo sapiens miR-6750 stem-loop Proteins 0.000 description 1
- 108091086502 Homo sapiens miR-874 stem-loop Proteins 0.000 description 1
- 108091070380 Homo sapiens miR-92a-1 stem-loop Proteins 0.000 description 1
- 108091070381 Homo sapiens miR-92a-2 stem-loop Proteins 0.000 description 1
- 108091068854 Homo sapiens miR-99a stem-loop Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091008051 MIR27A Proteins 0.000 description 1
- 108091007424 MIR27B Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 101150035777 sev gene Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1388—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Definitions
- Extracellular vesicles of mesenchymal cells from the umbilical cord for the treatment of osteoarticular and autoimmune diseases are included in the umbilical cord.
- the invention relates to the general field of biotechnology, and specifically relates to the field of regenerative medicine and the manufacture of therapy products based on human mesenchymal cells, specifically extracellular vesicles, for the treatment of osteoarticular and autoimmune diseases.
- vesicles naturally secreted by the cells during cell culture, since it has been seen that they have great potential to constitute cell-free therapies.
- researchers have studied the function of these vesicles in various fields, among them it has been found that they play an important role in intercellular communication, that they have an effect on the formation and/or modulation of diseases through their content, which corresponds to essentially proteins and RNA. It has been found especially that these vesicles contain a high quantity and variety, between 2000 to 3000 types of microRNA or miRNA. These molecules are non-coding RNA chains, which play an important role in the regulation of gene expression.
- a subset of the extracellular vesicles are exosomes (30 to 200 nm), which have already been used as delivery vehicles for different drugs.
- mesenchymal cell exosomes are used for the treatment of some diseases, such as glaucoma, US20190224242A1 (Tomarev et al, 2019-07-25), but the composition used and the properties observed in that document are far from the composition of the invention, for example in the application the exosomes have the markers CDllc + and CD63 + , while in the invention the markers CD63, CD81 and CD9 are required, to name only one difference.
- the invention aims at a composition of exosomes obtained from umbilical cord mesenchymal cells (UC-MSC) which contain miRNA and/or specific surface markers, for the treatment of osteoarticular and autoimmune diseases.
- U-MSC umbilical cord mesenchymal cells
- Figure 1 Treatment with the composition of the invention allows to reduce the severity of the lesion, in a murine model of osteoarthritis, Study 1.
- A) OA histology score (or OA score) shows a healthy joint (Sham , or placebo), the joint with osteoarthritis, and the joint with osteoarthritis treated with the composition of the invention (Exosome).
- FIG. 1 Treatment with the composition of the invention shows positive results in bone mineral density in a mouse model of osteoarthritis, Study 2.
- Figure 3 Treatment with the composition of the invention shows positive results in bone mineral density in a mouse model of osteoarthritis, Study 3.
- composition of the invention results in less proliferation than the control at both times.
- Treatment with the composition of the invention increases the proliferation of Tregs cells; characterized by having the markers CD4, FOXP3 and CD25.
- Peripheral blood mononuclear cells, activated with PHA (20pg/mL), treated with PBS control and with the composition of the invention the proliferation of Treg cells is shown on the third day of culture.
- the composition of the invention allows a greater proliferation than the control.
- FIG. 6 Treatment with the composition of the invention positively polarizes macrophage differentiation.
- Monocytes were isolated from peripheral blood mononuclear cells, which were cultured and differentiated into macrophages by the factors M-CSF and GM-CSF, after 6 days they were treated with PBS control and with the composition of the invention, A) proliferation of MI or pro-inflammatory macrophages 24 hours after the stimulus, is seen decreased by the composition of the invention sEV, B) proliferation of M2 macrophages or anti-inflammatory 24 hours after the stimulus, is seen increased by the composition of the invention sEV.
- the invention refers to a composition enriched in extracellular vesicles (EV) of mesenchymal cells of the umbilical cord, with specific markers and miRNA, where this composition is useful in the treatment of osteoarticular and autoimmune diseases, especially when injected into the sites of the injury to treat.
- EV extracellular vesicles
- the invention aims at a composition enriched in extracellular vesicles (EV) from umbilical cord mesenchymal cells, which consists of a set of EVs containing the miRNAs: hsa-miR-6126, hsa-miR-149-3p and hsa -miR-6780b-5p, among the 10 most abundant miRNAs, and additionally contain at least 5 of the following miRNAs: hsa-miR-574-5p, hsa-miR-6131, hsa-miR-6741-5p, hsa-miR -21-5p, hsa-miR-1290, hsa-miR-4530, hsa-miR-2861, hsa-miR-6088, hsa-miR-1307-5p and/or hsa-miR-6782-5p. and they have the surface markers CD63, CD81 and CD9
- the vesicles or exosomes contain the following miRNAs: hsa-miR-8078; hsa-miR-7150; hsa-miR-6750-5p; hsa-miR-6727-5p; hsa-miR-5585-3p; hsa-miR-4459; hsa-miR-4449; hsa-miR-3687; hsa-miR-3197; hsa-miR-1915-3p; hsa-miR-1285-5p; hsa-miR-1275; hsa-miR-1273h-5p; hsa-miR-1273d; hsa-miR-1237-5p; hsa-miR-874-3p; hsa-miR-671-5p; hsa-miR-424-5p; hsa-miR-3
- the EV contain a huge variety of miRNAs, in very different proportions, for the person skilled in the art it is evident that the subgroup of the 100 most abundant miRNAs is small, since they are usually sequenced and calculated. concentrations of about 2,000 to 3,000 miRNAs.
- the inventors have obtained cultures of specific umbilical cord mesenchymal cells (UC-MSC), from different donors, from which they have obtained the compositions of the invention, those that replicate the presence of specific markers, and the relative concentrations of miRNA indicated. These compositions of the invention have proven to be useful in the treatment of osteoarticular injuries and have a positive effect in models correlated with the treatment of autoimmune diseases, as will be demonstrated in the examples.
- U-MSC umbilical cord mesenchymal cells
- the vesicles of the composition of the invention contain at least 8 of the following miRNAs: hsa-m ⁇ R-574-5p, hsa-miR-6131, hsa-m ⁇ R-6741-5p, hsa -m ⁇ R-21-5p, hsa-miR-1290, hsa-miR-4530, hsa-miR-2861, hsa-miR-6088, hsa-m ⁇ R-1307-5p and/or hsa-m ⁇ R -6782-5p, among the 100 most abundant miRNAs.
- the vesicles may contain the surface markers N-cadherin and/or CD90 and/or CD44.
- the vesicles are in a concentration of between 5xl0 7 to lxlO 13 total particles per mL, and have a size between 30 to 300 nm.
- the invention relates to the method for obtaining the composition of the invention, in which the EVs are isolated from the culture supernatant of the umbilical cord mesenchymal cells expanded in vitro, where said cells express at least 2 of the surface markers N-cadherin, CD44, RANKL, CD105, CD56 and/or CD90 and are resuspended in a medium or vehicle free of animal components and proteins, with an osmolality between 250 and 310 mOsmol/L and a pH between 6 .0 and 8.0.
- the EVs are isolated from the culture supernatant of the umbilical cord mesenchymal cells expanded in vitro, where said cells express at least 2 of the surface markers N-cadherin, CD44, RANKL, CD105, CD56 and/or CD90 and are resuspended in a medium or vehicle free of animal components and proteins, with an osmolality between 250 and 310 mOsmol/L and a pH between 6 .0
- phosphate buffer or PBS Ringer's lactate
- Hypotemerosol ® Hypotemerosol ®
- Plasmalyte ® the essential thing is the osmolality and the pH, already indicated.
- the EVs are isolated from the supernatant by filtering and/or centrifugation, washed at least twice with a medium or vehicle free of animal components and proteins, with an osmolality between 250 and 310 mOsmol/L and a pH between 6.0 and 8.0, and finally they are resuspended in a medium or vehicle free of animal components and proteins, with an osmolality between 250 and 310 mOsmol/L and a pH between 6.0 and 8.0. It will be apparent to one skilled in the art that there may be different protocols for isolating extracellular vesicles from mesenchymal cell culture supernatant.
- the process of the invention does not depend on the protocol or system used for this separation, as long as it is efficient in separating vesicles with a size between 30 to 300 nm, so this separation can be carried out by any technique or instrument available at the time of preparation. carry out the invention.
- the umbilical cord mesenchymal cells, from which the EVs are obtained express at least 3 of the N-cadherin surface markers, CD44, RANKL, CD105, CD56 and/or CD90.
- the composition of the invention has specific activities, which make it useful for preparing a medicament for the treatment of osteoarticular and autoimmune diseases.
- the composition has been shown to promote cartilage regeneration; as well as the increase in bone mineral density in clinical pictures of osteoarthritis in vivo.
- the composition is useful for decreasing the proliferation of CD4+ T cells, and at the same time increasing the proliferation of T regs cells.
- the composition makes it possible to increase M2 macrophages, or anti-inflammatory CD206+ HLA-DR+ macrophages, and/or decrease MI macrophages, or pro-inflammatory macrophages or CD86+ HLA-DR+.
- composition is useful for the treatment of osteoarthritis, arthritis, osteoarthritis, for example.
- it is useful for the treatment of rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, type 1 diabetes mellitus, guillain-barre syndrome, chronic inflammatory demyelinating polyneuropathy, psoriasis, Graves' disease, Hashimoto's thyroiditis, myasthenia severe, vasculitis, Sjogren's syndrome, Hashimoto's thyroiditis, pernicious anemia, celiac disease, or graft-versus-host disease.
- Example 1 Obtaining the composition of the invention.
- Mesenchymal cells from the umbilical cord were obtained and it was verified that they had the markers N-cadherin, CD44, RANKL, CD105, CD56 and/or CD90. 3 batches of cells were obtained, in Table 1, below, the mesenchymal cell markers are shown, and of the selection condition of the invention, for each one of them.
- the cells thus validated were cultivated under the usual conditions of any mesenchymal cell culture, until confluence in a total volume of 650 mL, with a commercial medium (DMEM high in glucose; supplemented with 5% hPL, 1% L-Glut, 1% Pen/Strep). Subsequently, the cells were washed twice with PBS (Phosphate buffer, pH7.2; 290mOsm/L) and 650mL of induction medium (DMEM high in glucose; supplemented only with 1% L-Glut) was added.
- PBS Phosphate buffer, pH7.2; 290mOsm/L
- 650mL of induction medium DMEM high in glucose; supplemented only with 1% L-Glut
- the supernatant collected after each incubation 1 or 2 was centrifuged at 600 g at 4°C for 10 minutes to remove impurities.
- the supernatants from the previous centrifugation were processed in an ultracentrifuge at 100,000 g for 1 hour and 10 minutes at 4°C, this step was repeated until the total volume of the supernatant was processed.
- the supernatant was removed and the pellets were loosened using a vortex.
- the pellets were subjected to two washes in order to eliminate possible contaminants. For this, the pellets were resuspended in PBS. filtrate reaching a final volume of 10 ml, and centrifuged at 100,000 g at 4°C over night.
- hsa-miR-8078 hsa-miR-7150; hsa-m ⁇ R-6750-5p; hsa-m ⁇ R-6727-5p; hsa-m ⁇ R-5585-3p; hsa-miR-4459; hsa-miR-4449; hsa-miR-3687; hsa-miR-3197; hsa-m ⁇ R-1915-3p; hsa-m ⁇ R-1285-5p; hsa-miR-1275; hsa-miR-1273h-5p; hsa-m ⁇ R-1273d; hsa-m ⁇ R-1237-5p; hsa-m ⁇ R-874-3p; hsa-m ⁇ R-671-5p; hsa-m ⁇ R-
- Example 2 Application of the composition of the invention for the treatment of osteoarthritis.
- the compositions obtained in example 1 were used indistinctly, in a murine osteoarthritis model.
- the disease is induced by injecting collagenase into the joint, in this case the knee, on days 0 and 2, and then on days 7 and 14 the respective treatment is applied, also by injection into the joint. Then, on day 40, euthanasia is performed, and the intervened joint is analyzed.
- Each group was subdivided into 3, a first control group, which received placebo (PBS, 5mI_), a second control group in which the lesion is induced, but the treatment is not applied, so they maintain the osteoarthritis disease (OA) , and finally the group to which the injury is induced and the treatment of the invention is applied.
- PBS placebo
- 5ml_ Type VII Collagenase 1 U/5 m ⁇ , was applied to the joint by injection at the beginning of the experiment and on day 2 of the same, this for the lesion-only groups (OA) and for those subsequently treated.
- the animals of the third group received as treatment the composition of the invention adjusted so as to apply an amount of 2xl0 8 exosomes, the treatment was applied 2 times, on days 7 and 14 from the beginning of the experiment, in a volume of 5mI_
- OA score OA histology score
- Example 3 Immunosuppression test with the composition of the invention.
- Peripheral blood mononuclear cells were isolated, activated with PHA (20pg/mL) and stained with CTV (1:1000) to assess proliferation.
- Two experimental groups were considered: a) 10 pi ⁇ of PBS control and b) treated with a single dose of the composition of the invention (sEV's) with a quantity of total particles of 2xl0 8 , dissolved in 10pL of vehicle.
- sEV's composition of the invention
- the proliferation of helper T cells abbreviated as Th; CD4+
- Tregs CD4+FOXP3+CD25+
- Figure 4 shows the percentages of proliferation of Th lymphocyte cells on the third day of culture (Fig.
- FIG. 4a shows the fifth day of culture (Fig. 4b), where it is observed that treatment with the composition of the invention produced less proliferation.
- Figure 5 shows the percentage of Tregs cells, where it is observed that treatment with the composition of the invention (sEV's) increased the percentage of this population, on the third day of culture.
- Th cells correspond to a cell population with an important role in the adaptive immune response. These cells divide into Thl, Th2, and Thl7; all of them secrete cytokines to stimulate the proliferation and differentiation of cells involved in the immune response. There is evidence that T cells are present in greater numbers in organs with OA than in healthy controls.
- Treg cells are a subpopulation of CD4+ T cells that maintain homeostasis and tolerance within the immune system, regulating or suppressing other CD4+ and CD8+ T cells, and perhaps also B lymphocytes and dendritic cells. Treg cells can produce molecules with an immunosuppressive function such as TGF-b, IL-10 and adenosine.
- Example 4 Macrophage polarization assay with the composition of the invention
- Peripheral blood mononuclear cells were isolated and then, using a negative selection kit, the monocytes present were obtained. These monocytes were cultured and differentiated into macrophages using the factors M-CSF and GM-CSF. After six days of culture, two groups were established Experimental: a) control and b) treated with a single dose of the composition of sEV's of the invention, with a quantity of total particles of lxlO 9 .
- MI proinflammatory
- M2 CD206+ HLA-DR+
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Nanotechnology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/556,609 US20240209317A1 (en) | 2021-04-22 | 2022-04-22 | Umbilical cord mesenchymal cell extracellular vesicles for the treatment of osteoarticular and autoimmune diseases |
CN202280037365.4A CN117500922A (zh) | 2021-04-22 | 2022-04-22 | 用于治疗骨关节疾病和自身免疫性疾病的脐带间充质细胞的细胞外囊泡 |
JP2023565237A JP2024514273A (ja) | 2021-04-22 | 2022-04-22 | 骨関節疾患及び自己免疫疾患の処置のための臍帯間葉系細胞の細胞外小胞 |
EP22790655.9A EP4328307A1 (en) | 2021-04-22 | 2022-04-22 | Extracellular vesicles of umbilical cord mesenchymal cells for treating osteoarticular and autoimmune diseases |
BR112023021931A BR112023021931A2 (pt) | 2021-04-22 | 2022-04-22 | Composição enriquecida em vesículas extracelulares (ev) de células mesenquimais do cordão umbilical, método de obtenção da composição e uso da composição |
KR1020237040308A KR20230174269A (ko) | 2021-04-22 | 2022-04-22 | 골관절 질환 및 자가면역 질환 치료를 위한 제대 중간엽세포 세포외 소포(umbilical cord mesenchymal cell extracellular vesicles for the treatment of osteoarticular and autoimmune diseases) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163178229P | 2021-04-22 | 2021-04-22 | |
US63/178,229 | 2021-04-22 | ||
US202263330092P | 2022-04-12 | 2022-04-12 | |
US63/330,092 | 2022-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022221969A1 true WO2022221969A1 (es) | 2022-10-27 |
Family
ID=83723550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CL2022/050039 WO2022221969A1 (es) | 2021-04-22 | 2022-04-22 | Vesículas extracelulares de células mesenquimales de cordón umbilical para el tratamiento de enfermedades osteoarticulares y autoinmunes. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240209317A1 (es) |
EP (1) | EP4328307A1 (es) |
JP (1) | JP2024514273A (es) |
KR (1) | KR20230174269A (es) |
BR (1) | BR112023021931A2 (es) |
CL (1) | CL2023003152A1 (es) |
WO (1) | WO2022221969A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023240069A1 (en) * | 2022-06-06 | 2023-12-14 | The University Of Vermont And State Agricultural College | Extracellular vesicle micrornas and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160002597A1 (en) * | 2013-02-12 | 2016-01-07 | Reneuron Limited | Method of producing microparticles |
WO2019038660A1 (en) | 2017-08-21 | 2019-02-28 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | EXOSOMAL PROFILING FOR THE DIAGNOSIS AND MONITORING OF VASCULITE AND VASCULOPATHIES, INCLUDING KAWASAKI'S DISEASE |
US20190224242A1 (en) | 2018-01-25 | 2019-07-25 | The U.S. of America, as represented by the Secretary, Department of Health and Human Services | Exosomes and mirna to treat glaucoma |
-
2022
- 2022-04-22 KR KR1020237040308A patent/KR20230174269A/ko unknown
- 2022-04-22 BR BR112023021931A patent/BR112023021931A2/pt unknown
- 2022-04-22 WO PCT/CL2022/050039 patent/WO2022221969A1/es active Application Filing
- 2022-04-22 JP JP2023565237A patent/JP2024514273A/ja active Pending
- 2022-04-22 US US18/556,609 patent/US20240209317A1/en active Pending
- 2022-04-22 EP EP22790655.9A patent/EP4328307A1/en active Pending
-
2023
- 2023-10-20 CL CL2023003152A patent/CL2023003152A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160002597A1 (en) * | 2013-02-12 | 2016-01-07 | Reneuron Limited | Method of producing microparticles |
WO2019038660A1 (en) | 2017-08-21 | 2019-02-28 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | EXOSOMAL PROFILING FOR THE DIAGNOSIS AND MONITORING OF VASCULITE AND VASCULOPATHIES, INCLUDING KAWASAKI'S DISEASE |
US20190224242A1 (en) | 2018-01-25 | 2019-07-25 | The U.S. of America, as represented by the Secretary, Department of Health and Human Services | Exosomes and mirna to treat glaucoma |
Non-Patent Citations (7)
Title |
---|
ALONSO, M.L. ET AL.: "Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos", STEM CELL REVIEWS AND REPORTS, vol. 18, no. 3, 26 April 2021 (2021-04-26), pages 854 - 901, XP037746100, DOI: 10.1007/s1 2015-021-10155-5 * |
ASGARPOUR KASRA, SHOJAEI ZAHRA, AMIRI FATEMEH, AI JAFAR, MAHJOUBIN-TEHRAN MARYAM, GHASEMI FAEZEH, AREFNEZHAD REZA, HAMBLIN MICHAEL: "Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages", CELL COMMUNICATION AND SIGNALING, vol. 18, no. 1, 1 December 2020 (2020-12-01), XP093003100, DOI: 10.1186/s12964-020-00650-6 * |
COSENZA, S.RUIZ, M.MAUMUS, M.JORGENSEN, C.NOEL, D.: "Pathogenic or Therapeutic Extracellular Vesicles in Rheumatic Diseases: Role of Mesenchymal Stem Cell-Derived Vesicles", INT. J. MOL. SCI., vol. 18, 2017, XP055583118, DOI: 10.3390/ijms18040889 |
HUANG BO, HUANG LIN-FENG, ZHAO LING, ZENG ZONGYUE, WANG XI, CAO DAIGUI, YANG LIJUAN, YE ZHENYU, CHEN XIAN, LIU BIN, HE TONG-CHUAN,: "Microvesicles (MIVs) secreted from adipose-derived stem cells (ADSCs) contain multiple microRNAs and promote the migration and invasion of endothelial cells", GENES & DISEASES, ELSEVIER BV, NL, vol. 7, no. 2, 1 June 2020 (2020-06-01), NL , pages 225 - 234, XP093003089, ISSN: 2352-3042, DOI: 10.1016/j.gendis.2019.04.005 * |
LIANG CHENYU, LIU YANG, XU HUIFENG, HUANG JUNLING, SHEN YI, CHEN FAXIU, LUO MING: "Exosomes of Human Umbilical Cord MSCs Protect Against Hypoxia/Reoxygenation-Induced Pyroptosis of Cardiomyocytes via the miRNA-100-5p/FOXO3/NLRP3 Pathway", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, vol. 8, XP093003093, DOI: 10.3389/fbioe.2020.615850 * |
MATAS JOSE, ORREGO MARIO, AMENABAR DIEGO, INFANTE CATALINA, TAPIA-LIMONCHI RAFAEL, CADIZ MARIA IGNACIA, ALCAYAGA-MIRANDA FRANCISCA: "Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial", STEM CELLS TRANSLATIONAL MEDICINE, ALPHAMED PRESS, INC., US, vol. 8, no. 3, 1 March 2019 (2019-03-01), US , pages 215 - 224, XP093003107, ISSN: 2157-6564, DOI: 10.1002/sctm.18-0053 * |
MIANEHSAZ, E. ET AL.: "Mesenchymal stem cell -derived exosomes: a new therapeutic approach to osteoarthritis?", STEM CELL RESEARCH & THERAPY, vol. 10, no. 1, 2019, pages 1 - 13, XP055965127, DOI: 10.1186/s13287-019-1445-0 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023240069A1 (en) * | 2022-06-06 | 2023-12-14 | The University Of Vermont And State Agricultural College | Extracellular vesicle micrornas and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20240209317A1 (en) | 2024-06-27 |
CL2023003152A1 (es) | 2024-01-12 |
EP4328307A1 (en) | 2024-02-28 |
KR20230174269A (ko) | 2023-12-27 |
BR112023021931A2 (pt) | 2024-01-16 |
JP2024514273A (ja) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106902381B (zh) | 重组人源胶原蛋白原液、敷料以及它们的制备方法 | |
ES2880084T3 (es) | Terapias que usan células adiposas y secreciones celulares | |
ES2511791T3 (es) | Células madre mesenquimales positivas para ABCB5 como moduladoras de inmunidad | |
US20060247195A1 (en) | Method of altering cell properties by administering rna | |
ES2673861T3 (es) | Método novedoso para tratar el daño a la médula espinal utilizando el fragmento de hmgb1 | |
BR112019020667A2 (pt) | rna para tratamento de doenças autoimunes | |
ES2732317T3 (es) | Material de relleno dermocosmético y usos del mismo para fines estéticos | |
CN1107365A (zh) | 新型生理活性物质 | |
DE202016008300U1 (de) | Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen | |
WO2022221969A1 (es) | Vesículas extracelulares de células mesenquimales de cordón umbilical para el tratamiento de enfermedades osteoarticulares y autoinmunes. | |
KR102209937B1 (ko) | 생산성 향상 및 생리활성 강화를 위한 엑소좀의 생산방법 및 이의 응용 | |
JP2022510982A (ja) | オルガノイドの生体移植用組成物 | |
JP2017031137A (ja) | タンパク質の機能を保存する方法及びタンパク質の保管方法 | |
JP2023134693A (ja) | 人体抹消血液のNK細胞より高い水準のNCR、細胞毒性及びIFN-γ生産能力を有するメモリ様NK細胞の製造方法 | |
Viktorova et al. | Multipotent mesenchymal stem cells in clinical veterinary practice | |
JP7064197B2 (ja) | シュワン細胞分化促進剤及び末梢神経再生促進剤 | |
CN106574247A (zh) | 从全血中扩增成体干细胞的方法 | |
KR20150020112A (ko) | 메트포민이 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
JP2023536386A (ja) | Icam調節剤を用いた治療の方法 | |
CN117500922A (zh) | 用于治疗骨关节疾病和自身免疫性疾病的脐带间充质细胞的细胞外囊泡 | |
HRP20140247T1 (hr) | Cjepivo protiv raka | |
KR102179155B1 (ko) | 옥추출물을 이용한 골세포 분화 방법 | |
RU2129427C1 (ru) | Способ лечения заболеваний центральной нервной системы | |
JP4073986B2 (ja) | 脊髄潅流液 | |
US20060062766A1 (en) | Remedy for cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22790655 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18556609 Country of ref document: US Ref document number: 2023565237 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023021931 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237040308 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022790655 Country of ref document: EP Ref document number: 1020237040308 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280037365.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022790655 Country of ref document: EP Effective date: 20231122 |
|
ENP | Entry into the national phase |
Ref document number: 112023021931 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231020 |